Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
3.770
-0.020 (-0.53%)
Feb 27, 2026, 1:33 PM EST - Market open
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Iovance Biotherapeutics stock have a consensus rating of "Buy" and an average price target of $10.08, which forecasts a 167.37% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $20.
Price Target: $10.08 (+167.37%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 5 | 5 | 5 | 6 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 12 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | +191.78% | Feb 25, 2026 |
| Citizens | Citizens | Hold → Buy Upgrades $5 | Hold → Buy | Upgrades | $5 | +32.63% | Feb 25, 2026 |
| Barclays | Barclays | Buy Maintains $9 → $10 | Buy | Maintains | $9 → $10 | +165.25% | Dec 17, 2025 |
| Barclays | Barclays | Buy Maintains $4 → $9 | Buy | Maintains | $4 → $9 | +138.73% | Nov 24, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 → $17 | Strong Buy | Maintains | $20 → $17 | +350.93% | Nov 6, 2025 |
Financial Forecast
Revenue This Year
416.30M
from 263.50M
Increased by 57.99%
Revenue Next Year
635.40M
from 416.30M
Increased by 52.63%
EPS This Year
-0.59
from -1.09
EPS Next Year
-0.20
from -0.59
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 567.4M | 812.0M | |||
| Avg | 416.3M | 635.4M | |||
| Low | 333.2M | 450.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 115.3% | 95.1% | |||
| Avg | 58.0% | 52.6% | |||
| Low | 26.5% | 8.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.40 | -0.02 | |||
| Avg | -0.59 | -0.20 | |||
| Low | -1.01 | -0.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.